Mojgan Ahmadzadeh

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Blood 114:1537-44. 2009
  2. pmc Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 176:7726-35. 2006
  3. pmc IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 30:294-302. 2007
  4. pmc FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 112:4953-60. 2008
  5. doi request reprint Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma
    Alena Gros
    National Cancer Institute, Bethesda, MD, USA
    Clin Cancer Res 18:5212-23. 2012
  6. pmc Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 179:4919-28. 2007
  7. pmc Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells
    Takashi Inozume
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Immunother 33:956-64. 2010
  8. doi request reprint Immunogenicity of somatic mutations in human gastrointestinal cancers
    Eric Tran
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Science 350:1387-90. 2015
  9. pmc Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
    Xin Yao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 119:5688-96. 2012
  10. pmc Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 30:438-47. 2007

Detail Information

Publications14

  1. pmc Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Blood 114:1537-44. 2009
    ..These findings suggest that the tumor microenvironment can lead to up-regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune responses...
  2. pmc Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 176:7726-35. 2006
    ..004) with the ability of these TILs to mediate tumor regression following adoptive transfer...
  3. pmc IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 30:294-302. 2007
    ....
  4. pmc FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 112:4953-60. 2008
    ....
  5. doi request reprint Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma
    Alena Gros
    National Cancer Institute, Bethesda, MD, USA
    Clin Cancer Res 18:5212-23. 2012
    ..Myeloid-derived suppressor cells (MDSC) have emerged as an immune-regulatory cell type that is expanded in tumor-bearing mice, but less is known about their immune-suppressive role in patients with cancer...
  6. pmc Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 179:4919-28. 2007
    ....
  7. pmc Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells
    Takashi Inozume
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Immunother 33:956-64. 2010
    ..As a consequence, the PD-1 receptor can be a useful biomarker for enriching tumor-specific T cells from fresh melanomas...
  8. doi request reprint Immunogenicity of somatic mutations in human gastrointestinal cancers
    Eric Tran
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Science 350:1387-90. 2015
    ..Thus, a high frequency of patients with common gastrointestinal cancers harbor immunogenic mutations that can potentially be exploited for the development of highly personalized immunotherapies. ..
  9. pmc Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
    Xin Yao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 119:5688-96. 2012
    ..All 5 clinical trials are registered at www.clinicaltrials.gov as NCT00001832, NCT00096382, NCT00335127, NCT00509496, and NCT00513604...
  10. pmc Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 30:438-47. 2007
    ....
  11. pmc TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:5215-23. 2005
    ....
  12. pmc IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 29:313-9. 2006
    ..These studies suggest an important role for interleukin-7 in the treatment of patients with lymphopenia...
  13. pmc IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients
    Mojgan Ahmadzadeh
    Surgery Branch, NCI, NIH, Bethesda, MD 20892, USA
    Blood 107:2409-14. 2006
    ..Our findings suggest that selective inhibition of IL-2-mediated enhancement of regulatory T cells may improve the therapeutic effectiveness of IL-2 administration...
  14. pmc Interleukin-2-dependent mechanisms of tolerance and immunity in vivo
    Paul A Antony
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 176:5255-66. 2006
    ..Lastly, administration of anti-IL-2 plus exogenous IL-15 to tumor-bearing mice enhanced the adoptive immunotherapy of cancer. Therefore, Th cell-derived IL-2 paradoxically controls both tolerance and immunity to a tumor/self-Ag in vivo...